Eing B R, Becker A, Sohns A, Ringelmann R
Institut für Medizinische Mikrobiologie und Immunologie, Städtisches Klinikum Karlsruhe, Germany.
J Clin Microbiol. 1998 Jul;36(7):2023-9. doi: 10.1128/JCM.36.7.2023-2029.1998.
The new Roche Cobas Amplicor Mycobacterium tuberculosis assay, which is a semiautomated version of the manually performed Roche Amplicor M. tuberculosis test, was compared to culture and an IS6110-based in-house PCR protocol. A total of 1,681 specimens from 833 patients, including specimen types other than sputum, were tested in parallel by both the in-house PCR and the Cobas Amplicor M. tuberculosis assay. After we resolved discrepant PCR results, the sensitivity, specificity, and positive and negative predictive values for the Cobas Amplicor M. tuberculosis assay were 66.33, 99.71, 94.36, and 97.66%, respectively. The corresponding values for the in-house PCR were 91.08, 99.85, 97.87, and 99.37%, respectively. For culture- and smear-positive specimens, the sensitivity of the Cobas Amplicor M. tuberculosis test was 96.42% (in-house PCR, 100%). If only smear-negative sputum specimens were considered, the Cobas Amplicor M. tuberculosis assay exhibited a sensitivity of 45.45% (in-house PCR, 63.63%) relative to that of culture. With a modified protocol for DNA extraction (washing of samples plus ultrasonication), both PCR methods performed better with gastric aspirates than with sputum samples (sensitivity of the Cobas Amplicor M. tuberculosis assay with smear-negative gastric aspirates, 70.00%; sensitivity of in-house PCR, 90.00%). With dithiothreitol being used for liquefaction of specimens in this study, the Cobas Amplicor M. tuberculosis assay exhibited an inhibition rate of 9.16%. In our view, the new Cobas Amplicor M. tuberculosis test (i) is well suited for typing of smear-positive specimens, (ii) may also be applied to gastric aspirates and other types of specimens if DNA extraction methods are modified appropriately, and (iii) exhibits a sensitivity with smear-negative sputum specimens which makes it recommendable that a minimum of three samples from the same patient be tested.
新型罗氏Cobas Amplicor结核分枝杆菌检测法是手工操作的罗氏Amplicor结核分枝杆菌检测法的半自动版本,我们将其与培养法以及基于插入序列6110(IS6110)的内部聚合酶链反应(PCR)方案进行了比较。对来自833例患者的总共1681份标本(包括痰以外的标本类型)同时采用内部PCR和Cobas Amplicor结核分枝杆菌检测法进行检测。在我们解决了不一致的PCR结果后,Cobas Amplicor结核分枝杆菌检测法的灵敏度、特异度、阳性预测值和阴性预测值分别为66.33%、99.71%、94.36%和97.66%。内部PCR的相应值分别为91.08%、99.85%、97.87%和99.37%。对于培养及涂片阳性的标本,Cobas Amplicor结核分枝杆菌检测法的灵敏度为96.42%(内部PCR为100%)。如果仅考虑涂片阴性的痰标本,相对于培养法,Cobas Amplicor结核分枝杆菌检测法的灵敏度为45.45%(内部PCR为63.63%)。采用改良的DNA提取方案(样本洗涤加超声处理)后,两种PCR方法对胃抽吸物的检测效果均优于痰标本(涂片阴性胃抽吸物的Cobas Amplicor结核分枝杆菌检测法灵敏度为70.00%;内部PCR灵敏度为90.00%)。在本研究中使用二硫苏糖醇对标本进行液化处理时,Cobas Amplicor结核分枝杆菌检测法的抑制率为9.16%。我们认为,新型Cobas Amplicor结核分枝杆菌检测法(i)非常适合对涂片阳性标本进行分型,(ii)如果对DNA提取方法进行适当改良,也可应用于胃抽吸物及其他类型的标本,(iii)对涂片阴性痰标本的检测灵敏度表明,建议对同一患者至少检测三份标本。